Platinum Industries Share Price: Target 2026 to 2030, Valuation and Risk

Platinum Industries share price today

The Platinum Industries share price closed near ₹224.60 on 10 September 2026, about 30.9% below its 52-week high of ₹325.10 and roughly 21% above its 52-week low of ₹185.26. Market capitalisation was around ₹1,272 crore, trailing EPS was ₹8.91, and the stock therefore traded at about 25.2 times trailing earnings and 2.78 times a book value of ₹80.81 per share. The quote above keeps moving after publication; every ratio and scenario input below stays fixed to that cut-off.

The investment tension in this name is unusually sharp. The five-year record in the 5 August 2026 universe snapshot shows sales compounding at 38.22% a year and profit at 61% a year. The trailing twelve months captured from Yahoo Finance on 10 September 2026 show revenue down 5.6% year on year and earnings down 12.5%. Those two facts describe the same company. One of them is about a young business scaling from a small base; the other is about what is happening right now.

Platinum Industries makes additives that go inside PVC and CPVC. It is a supplier to pipe, profile, cable and film converters rather than a consumer brand, which means its volumes track the plastics processing cycle and its realisations track input costs. That is the frame within which any target exercise has to sit.

What Platinum Industries actually makes

The company was incorporated in 2016 and is headquartered in Mumbai. It manufactures PVC stabilisers, CPVC additives, metallic stearates, lubricants and related speciality chemicals, selling in India and internationally.

Product family	What it is	Where it ends up	Economic characteristic
PVC stabilisers	Lead-based and non-lead-based heat stabiliser systems	Plumbing pipes and fittings, profiles, wires and cables	Volume-linked additive priced against input costs
CPVC additives and add packs	Additive systems formulated for chlorinated PVC	Plumbing pipes and fittings, and CPVC products generally	Tied to the pace of CPVC adoption
Metallic stearates	Calcium, zinc, barium, magnesium and aluminium soaps	Films, sheets, PVC and SPC floorings, packaging, plastisols	Broad industrial use, many suppliers
Lubricants and waxes	PE and OPE waxes and lubpacks	Processing aids inside PVC and CPVC compounds	Sold alongside the stabiliser range
CPVC compounds	Ready-to-process compounds for converters	CPVC pipe and fitting production	Moves the company one step down the chain
Regulated-application grades	Grades for medical tubing, disposable oxygen masks and blood bags	Healthcare disposables	Qualification-heavy, slower for a customer to switch

Two things in that list deserve attention. The first is that the company sells both lead-based and non-lead-based stabilisers, and the split between them is not among the figures captured here. Those two families carry different customer approvals and different pricing, so the mix matters more than the combined revenue line suggests. The second is the move into CPVC compounds and regulated-application grades. Compounds carry more revenue per tonne than an additive pack, and medical grades are harder to displace once qualified. Both are the kind of shift that would show up as margin before it shows up as a narrative.

The trailing twelve months have gone backwards

The most recent operating picture is not a continuation of the growth record. On the twelve-month figures captured on 10 September 2026, revenue was ₹444 crore and EBITDA ₹59 crore, with revenue 5.6% lower than a year earlier and earnings 12.5% lower.

Trailing measure	Value	Reading
Revenue	₹444 Cr	The base for every margin below
EBITDA	₹59 Cr	About 13% of revenue
Operating margin	10.67%	Thin for a business described as speciality
Net margin	11.35%	Implies trailing profit near ₹50 Cr
Revenue growth, year on year	-5.6%	Sales contracted
Earnings growth, year on year	-12.5%	Profit fell faster than sales
Trailing EPS	₹8.91	The starting point of the scenario model

The detail worth pausing on is that net margin sits above operating margin. That ordering is unusual. It normally means either meaningful non-operating income, which would be consistent with ₹143 crore of cash sitting on the balance sheet, or a low effective tax charge, or both. Whichever it is, part of the reported profit is not being earned by selling stabilisers, and the portion that is not should be treated differently when it is projected forward for five years.

Profit falling faster than sales is the second signal. It says operating leverage is working in reverse: the cost base did not shrink as quickly as the top line. In an additive business that is what a weak realisation cycle looks like, though the captured figures do not separate volume from price, so this remains an inference rather than a measurement.

What the five-year record does and does not prove

Here is the limitation stated plainly, because it changes how much weight the long-run numbers can carry. No year-by-year financial statement table was captured for this company in this research pass, and no quarterly series was captured either. What exists is the trailing twelve-month set from Yahoo Finance, and the five-year growth rates and return on capital carried in the 5 August 2026 universe snapshot, which is Screener-derived. Nothing between those two points has been estimated, and this article contains no quarterly figures for that reason.

Growth and return measure	Value	Where it was captured
Five-year sales CAGR	38.22%	Universe snapshot (Screener-derived), 5 August 2026
Five-year profit CAGR	61%	Universe snapshot (Screener-derived), 5 August 2026
Return on capital employed	15.74%	Universe snapshot (Screener-derived), 5 August 2026
Trailing revenue growth	-5.6%	Yahoo Finance, 10 September 2026
Trailing earnings growth	-12.5%	Yahoo Finance, 10 September 2026
Market capitalisation	₹1,234 Cr then, ₹1,272 Cr now	5 August snapshot and 10 September 2026

A 61% five-year profit CAGR in a company incorporated in 2016 is largely a base effect. Compounding from a small starting number produces large percentages that say more about where the business began than about where it can go. The arithmetic makes this obvious: a rate of that order sustained for another five years would multiply profit more than ten times, which no additive maker achieves against an installed competitive base.

The more useful number in that table is ROCE of 15.74%. A business growing profit at 61% while earning 15.74% on capital is a business that has been adding capital roughly as fast as it has been adding profit. That is normal for a young manufacturer building capacity, and it is also why the growth rate on its own is not evidence of pricing power. The test of pricing power is whether ROCE rises as the new capacity fills, and one captured reading cannot answer that. The fundamental analysis guide sets out how a return ratio and a growth rate should be read together rather than separately.

Balance sheet: net cash and almost no debt

This is the clearest strength in the captured figures, and it is not a small one for a micro-cap chemical manufacturer.

Balance-sheet item	10 September 2026	Why it matters
Total debt	₹10 Cr	Negligible against equity and against cash
Total cash	₹143 Cr	Funds working capital and capacity without a lender
Net cash	₹133 Cr	Roughly a tenth of market capitalisation
Debt to equity	2.29%	Effectively an unlevered balance sheet
Book value per share	₹80.81	Price to book of 2.78 times
Return on capital employed	15.74%	The return earned on capital already committed

A company with ₹133 crore of net cash does not face a refinancing question, and in a cyclical additive business that matters because the cycle can absorb working capital without warning. It also means the enterprise value is meaningfully below the market capitalisation, so the operating business is being valued at less than the headline P/E implies. The counterpart is that idle cash drags on return on equity, and that some of the trailing profit is probably being generated by that cash rather than by the plants. The debt-to-equity guide explains why a ratio this low changes which risks are worth worrying about and which are not.

Ownership and float

Promoters held 73.32% on the captured date, leaving a public float of about 26.68%. On a market capitalisation of ₹1,272 crore, that float is worth roughly ₹340 crore, which is small enough that ordinary buying or selling can move the price more than the news behind it does.

Two ownership details are not among the captured figures and should be read off the latest exchange filing rather than assumed. The first is the split of the float between institutional and retail holders. The second is whether any part of the promoter holding is pledged, which is a standard check for a promoter-dominated micro-cap and cannot be inferred from the holding percentage alone.

What the Platinum Industries share price already reflects

Valuation measure	10 September 2026 reading	Interpretation
Closing price	₹224.60	A fixed research input, not a live figure
Market capitalisation	₹1,272 Cr	Micro-cap, with the liquidity that implies
Trailing EPS	₹8.91	Yahoo Finance trailing earnings
Price to earnings	25.21×	Price divided by trailing EPS
Price to book	2.78×	Against book value of ₹80.81
Return on capital employed	15.74%	Respectable, not exceptional
Dividend yield	Not captured	The case rests on reinvestment, not income
52-week range	₹185.26 to ₹325.10	The close sits 30.91% below the high

Twenty-five times trailing earnings is not a demanding multiple for a chemical company that grows. It is a demanding multiple for one whose trailing revenue and profit are both falling, because the multiple is being paid on an earnings figure that has already declined and may decline further before it turns. The 30.9% drawdown from the high shows the market has repriced some of that, but a drawdown is not by itself a valuation argument. What matters is the level, not the distance travelled to reach it. The P/E ratio guide covers why a trailing multiple on contracting earnings behaves differently from the same multiple on growing earnings.

For comparison of method rather than of merit, the same framework applied to Kronox Lab Sciences, Vinati Organics and Fineotex Chemical shows how differently the speciality chemical label can behave across return profiles and end markets.

Valuation framework

The scenario model starts with TTM EPS of ₹8.91. For each year it applies EPS_TTM × (1 + growth)^(year − 2026 + 112/365) × exit P/E, then rounds the result to the nearest ₹5. The 112/365 factor represents the fraction of the first forecast year remaining from 10 September to 31 December. Dividends are excluded, and the framework itself is described in full in the stock valuation method guide.

Scenario	Annual EPS growth	Exit P/E	Business interpretation
Bear	6%	16×	The additive cycle stays weak, compounds and medical grades scale slowly, and the market rates it as a commodity supplier
Base	12%	22×	Trailing contraction proves cyclical, volumes recover with pipe demand, and the multiple settles slightly below today’s
Bull	18%	30×	CPVC compounds and regulated-application grades lift mix, ROCE rises as capacity fills, and the multiple re-rates modestly

Three choices in that table are deliberate. The growth rates are all far below the 61% five-year profit CAGR, because a base effect cannot be extrapolated and because the trailing twelve months are negative, so even the bear case of 6% requires the current decline to stop. The multiples are anchored below to modestly above the present 25.21 times, since assuming both strong growth and permanent multiple expansion would simply restate an optimistic view twice. And the spread between bear and bull is wide, which is honest for a micro-cap whose earnings direction has just reversed.

Platinum Industries share price target 2026 to 2030

The grid above is produced only from the disclosed EPS, growth and exit-multiple inputs, applied year by year with the partial-year convention stated above. It does not model a fresh share issue, a capacity addition funded from the cash pile, an acquisition, an exceptional item, a change in the tax charge, or the non-operating income that appears to be flowing through the current net margin. It also cannot model the quarter-by-quarter path, since no quarterly figures were captured. Those inputs should be revised as soon as the next reported result is available.

Risks that can break the framework

The first risk is the one already visible in the numbers: trailing revenue and profit are both contracting, and the model’s starting EPS of ₹8.91 is therefore a declining figure rather than a rising one. If the decline continues for another year, every scenario begins from a lower base than the one used here.

The second is the nature of the product. PVC and CPVC additives are formulated inputs sold to converters, and realisations move with resin and metal input costs. Compression between input costs and selling prices shows up quickly in a 10.67% operating margin, and there is not much cushion in that number.

The third is profit quality. Net margin above operating margin points to income that is not operating income, and a valuation framework built on trailing EPS implicitly projects that component forward at the same growth rate as the manufacturing business. That is unlikely to be right in either direction.

The fourth is disclosure. Customer concentration, the lead versus non-lead revenue split, export share, capacity utilisation and any pledge against promoter holding are all absent from the captured figures. Each of them could change the reading materially, and none of them has been assumed here.

The fifth is structural: a public float worth roughly ₹340 crore, a promoter-dominated register and a micro-cap listing together mean the price can move on flows rather than fundamentals, in both directions.

What would change the picture

These signals do not arrive together, and they do not carry equal weight. The first one to watch for is margin defence, because it lands in the very next result and needs no new disclosure to be read. If the operating margin holds while revenue is still soft, the cost base is being managed and the contraction is being absorbed rather than compounded. If it gives way, everything below this line becomes academic, because a better product mix announced against a collapsing margin cannot be valued.

Revenue direction is the second signal, and it needs more than one reading. The model starts from an EPS figure that is falling, so a single period of positive year-on-year growth would not establish a turn on its own; it could as easily be a restocking bounce or a soft comparable. Two consecutive periods of positive growth with the margin intact is the minimum that would justify treating ₹8.91 as a floor rather than a waypoint. A further period of decline instead would mean every scenario here begins from a lower number than the one used.

The third signal is slower to arrive and worth more than either of the first two. A disclosure separating operating profit from treasury income would change the framework rather than one input inside it, because the grid compounds a single blended EPS forward at a single growth rate. Split that figure and the share of earnings actually produced by the plants becomes visible, and a smaller genuinely operating base compounding at a credible rate is a different investment from a larger blended one compounding at the same rate. A good top-line quarter changes an input; that disclosure changes the model.

Mix sits behind all three. A separately reported line for CPVC compounds and regulated-application grades would be the strongest confirmation that the business is moving up the chain, but it only becomes decision-relevant once the margin has been defended and the top line has stopped falling. Two things sit outside this sequence altogether and would force a reassessment whenever they appear: a pledge against promoter holding, and the cash balance being committed to new capacity before the existing asset base has demonstrated its return.

Monitoring scorecard

Question to ask each result	Constructive evidence	Warning sign
Has the contraction stopped?	Revenue turns positive year on year	A further period of decline
Is the margin defended?	Operating margin holds above 10.67%	Margin slips into single digits
Where is profit coming from?	Operating profit grows faster than net profit	Net profit propped up by treasury income
Is the mix improving?	Compounds and medical grades disclosed separately and rising	Only a combined revenue line
Is capital earning?	ROCE moves above 15.74%	Capacity added while ROCE falls
Is the balance sheet intact?	Net cash maintained, debt to equity near 2.29%	Borrowing added to fund working capital
Is ownership stable?	Promoter holding steady and unpledged	Pledge disclosed or holding reduced

FAQ

What is the Platinum Industries share price target for 2026?

The 2026 figure in the grid above is produced by applying the chosen annual EPS growth rate to trailing EPS of ₹8.91 for the fraction of the year remaining after 10 September, then multiplying by the exit P/E for that scenario. Because only 112 of 365 days of 2026 remain from the cut-off, the 2026 number is close to a valuation of current earnings at each assumed multiple. It is a scenario output, not a forecast or a recommendation.

What is the Platinum Industries share price target for 2030?

The 2030 figure compounds the same trailing EPS forward by four and a bit years at each scenario’s growth rate and applies that scenario’s exit multiple. The spread between the bear and bull outcomes is deliberately wide because the company’s trailing earnings growth has just turned negative year on year. Read it as a range of arithmetic outcomes under stated assumptions, not as a price expectation.

What does Platinum Industries do?

It manufactures and sells PVC stabilisers, CPVC additives, metallic stearates, lubricants and related speciality chemicals in India and internationally. Its products go into plumbing pipes and fittings, profiles, wires and cables, films and sheets, floorings, packaging and regulated applications such as medical tubing, disposable oxygen masks and blood bags. It was incorporated in 2016 and is based in Mumbai.

Who are the promoters of Platinum Industries?

Promoter holding stood at 73.32% on 10 September 2026, leaving a public float of about 26.68%. The identities of the individual promoters and any pledge against their holding are not among the figures captured for this article and should be read from the current shareholding pattern filed with the exchange.

What is the Platinum Industries share price today on the NSE?

The live quote at the top of this page tracks PLATIND on the NSE and updates after publication. The fixed research reading used throughout this article is the ₹224.60 close of 10 September 2026, against a 52-week range of ₹185.26 to ₹325.10.

When did Platinum Industries list on the stock exchange?

The company was incorporated in 2016 and its shares trade on the NSE under the symbol PLATIND. The exact listing date is not among the figures captured for this article; the NSE quote page linked below carries the listing details along with every subsequent corporate filing.

Related research

• Kronox Lab Sciences share price target
• Vinati Organics share price target
• Fineotex Chemical share price target
• How to value a stock: the method behind every target here
• P/E ratio formula, meaning and calculation
• Fundamental analysis of stocks: a practical Indian guide
• Debt-to-equity ratio: formula, meaning and how to use it

Sources and methodology

• Platinum Industries on Screener.in — general company reference
• Platinum Industries quote and filings on NSE
• Platinum Industries company website

Price, 52-week range, market capitalisation, trailing EPS, price to earnings, price to book, book value, total debt, cash, debt to equity, trailing revenue, EBITDA, operating and net margin, year-on-year growth rates, promoter holding and the business description were captured from Yahoo Finance after the completed session of 10 September 2026. The five-year sales and profit CAGRs, the return on capital employed and the market capitalisation recorded on that date come from the 5 August 2026 Gale universe snapshot, which is Screener-derived; no Screener financial tables were captured for this company. No year-by-year statement table and no quarterly series were captured either, which is why neither appears above and why nothing between the five-year rates and the trailing twelve months has been reconstructed.

Analytical judgment begins after those figures. The reading of net margin above operating margin as non-operating income, the treatment of the five-year profit CAGR as a base effect, the interpretation of ROCE alongside that growth rate, the assessment of float and disclosure risk, and the three growth-and-multiple pairs used in the scenario framework are all interpretation, stated so that a reader can disagree with each one separately.

---

This article is research and education, not personalised investment advice or a recommendation to transact. Gale is not a SEBI-registered investment adviser. The scenarios are illustrations, not guarantees. Verify current exchange filings, liquidity, corporate actions and suitability, and consult a registered adviser before acting.